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ABSTRACT - Osteogenesis imperfect (OI) is a group of genotypically and phenotypically 
diverse disorders of connective tissue characterized by bone fragility. The classic typing 
of OI includes: type I (mildest), type II (perinatally lethal), type III (most severe non-
lethal) and type IV (moderate). Diagnosis and accurate typing of mild and moderate 
types of OI are challenging due to the heterogeneity of OI and the lack of diagnostic 
criteria. We did a retrospective review of 84 patient charts with a diagnosis of mild and 
moderate forms of OI. We report on their diagnostic experience with the goal of 
evaluating the role of genotyping in establishing and confirming a diagnosis of mild or 
moderate OI. Our analysis supports the fact that no set of clinical data is diagnostic in 
these cases and genetic testing has valuable utility. We further constructed a genotype-
phenotype map of our patient population, which can serve as an expandable tool for 
clinicians and families in the ongoing management of patients with mild and moderate 
types of OI. 
 
INTRODUCTION 
Classification of OI – Osteogenesis Imperfecta (OI) is a heterogenous group of skeletal 
dysplasias characterized by bone fragility and therefore susceptibility to fractures. The 
spectrum of severity of OI ranges from perinatally lethal to nearly asymptomatic, with 
individuals who only have a mild propensity to fractures. The most widely accepted 
classification of OI, which has remained the basis of the present day nosology, came in 
1979 by Sillence et al. based on clinical characteristics and radiographic features. Type I 
OI is the most common and mildest presentation with decreasing frequency of fractures 
after puberty. Type II is perinatally lethal with multiple congenital fractures, 
micromelia and severe lung disease.  Types III is the most severe non-lethal form 
presenting with multiple (congenital) fractures and severe and progressive bone 
deformities.  Type IV is an intermediate group that encompasses presentations that 
cannot otherwise be categorized into the other types.  
  
In 2004, Glorieux and Rauch expanded the original Sillence classification by adding 
types V–VII. As more genetic causes of OI were discovered, nomenclature revisions 
have been made to include up to OI type XIV (Forlino et al., 2011). Currently, there are a 
total of 17 genetic causes of OI described in the literature (Van Dijk and Sillence, 2014). 
There is ongoing debate about classification and subdivisions into different types since 
many new types of OI are not distinguishable clinically from the classically defined 
Sillence types (van Dijk et al., 2010).  
 
Genotype-Phenotype Relationship – OI is as diverse genotypically as it is 
phenotypically. The genetic defect is either directly or indirectly related to the 
biosynthesis of type 1 collagen, the main structural constituent of bones, tendons and 
ligaments. The individuals that fall into the four classic Sillence categories comprise 
over 90% of cases of OI and are heterozygous for dominant mutations of either the 
Col1α1 or Col1α2 genes, which respectively encode the proα1(I) and proα2(I) chains of 
type I procollagen (Engel and Prockop, 1991; Byers et al. 1991). Type I collagen is a 
heterotrimer composed of two alpha 1 and one alpha 2 chains. The peptide sequence of 
the chains contains uninterrupted repeats of Gly-X-Y. The glycine residue in every third 
position of the chains is necessary for the correct formation of the triple helix (Ben 
Amor et al, 2011).  
 
The mildest phenotype (type I OI) is usually a consequence of a quantitative defect of 
collagen type I (Byers 2000 and 2002). In these cases only about half the normal 
amount of type I collagen is produced because a nonsense, frameshift or splice site 
mutation has introduced premature termination of Col1α1, resulting in degradation of 
non-sense mRNA. Rarely, substitutions for glycine by small amino acids (cysteine, 
alanine and serine) near the N-terminus of either the alpha 1 or alpha 2 chains result in 
type I OI as well.   
 
On the other hand, more severe phenotypes are typically a result of mutations that 
disrupt the structure of either chain of type I collagen. Most commonly, mutations that 
replace the glycine residues of the triple helix are responsible because they delay helix 
formation and prolong duration of post-transcriptional modifications, which ultimately 
produce structurally defective collagen. The resulting phenotypes vary in severity, 
causing the dominantly inherited OI types II-IV (van Dijk et al., 2012). Less commonly 
these phenotypes can result from mutations in the C-terminus, insertion/deletion or 
missense mutations that cause structural abnormalities in collagen type I chains as well.  
 
These genotype-phenotype correlations are by no means absolute. Establishing 
correlations are further complicated by the fact that most OI mutations are unique. To 
date, there have been more than 2000 different mutations of type I collagen reported in 
a public access database (http://www.le.ac.uk/ge/collagen/) (Dalgleish, 1998).   
 
The pathogenic pathways responsible for the remaining cohort of OI patients who do 
not have a dominantly inherited collagen mutation, have been attributed to null 
mutations of genes that interact with collagen post-translationally (Marini and Blissett, 
2013). Type V OI is an exception overall in that it has distinct clinical features and is a 
result of one specific dominantly inherited mutation in IFITM5. The other non-Sillence 
types of OI range in severity from moderate to lethal and are inherited in an 
autosomally recessive manner. So far, genes have been identified that are involved in 
collagen folding (CRTAP, LEPRE1 and PPIB), chaperoning (FKBP10 and SERPINH1), 
modification and cross-linking (PLOD2), bone mineralization (SERPINF1) and bone cell 
differentiation (SP7, TMEM38B and WNT1) (Marini and Blissett, 2013). 
 
Diagnostic Dilemma – There are no specific criteria set for the diagnosis of OI. 
Clinically, the hallmark feature is the presence of fractures in the absence of trauma. 
Blue/grey sclera, dentinogenesis imperfecta (DI), hearing loss and other bone 
deformities vary in presentation. Historically, biochemical collagen screening has been 
the gold standard of confirming an OI diagnosis. Collagen screening involves taking a 
skin biopsy, followed by culture of the dermal fibroblasts, and biochemical assay of the 
excreted collagen showing reduced or abnormal procollagen (Steiner et al., 1996; 
Cabral et al., 2006). This is an invasive, time-consuming procedure, often taking up to 
two months, and typically providing definitive identification of a collagen defect in up to 
90% of cases (Wenstrup et al., 1990). With the discovery of causative mutations in 
Col1α1 and Col1α2, confirmatory molecular testing for mutations in these genes can be 
performed on a blood or tissue sample providing results in 4-8 weeks. With accurate 
clinical diagnosis, more than 95% of individuals with OI have a mutation detected with 
genomic sequencing (Sykes et al., 1990; Körkkö et al., 1998).  
 
The heterogeneity of OI can be a confounding factor in its diagnosis. When a severe 
phenotype is present, any qualified physician can diagnose the disease. Milder 
phenotypes are more difficult to diagnose. There are other conditions that have 
significant clinical overlap with OI including Ehlers Danlos Syndrome (EDS) 
kyphoscoliotic type (type VIA), EDS arthrochalasia type (types VIIA and VIIB) and EDS 
dermatosparaxis type (type VIIC) to name some (Steiner et al., 2013). The differential 
diagnosis also includes premature aging syndromes in which fractures may be the first 
manifestation and precede other clinical features (Van Dijk and Sillence, 2014). 
Furthermore, non-accidental injury as a result of child abuse can present similar to OI 
and importantly needs to be distinguished, though the two can coexist.  
 
The diagnostic dilemma of OI is two-fold. In the mildest form or type I, it is not always 
obvious whether OI exists or fracturing is due to another bone disease, (child) abuse or 
an unknown cause. In the moderate form or type IV, the true severity of the condition 
and whether the patient has been typed accurately can be subjective and based on 
presenting clinical features at any given time. For example, if an unrelated 5 year old 
and 50 year old both have had 5 fractures and do not exhibit other features, the 
younger patient’s condition is likely to be classified as more severe (type IV) while the 
older patient is likely to be classified as more mild (type I) even though they may have 
the same genotype and similar phenotypes. Therefore, genetic testing has valuable 
utility in establishing and confirming a diagnosis of OI in a quick, non-invasive and 
accurate fashion. This in turn informs medical management, administration of 
appropriate molecular therapies and evaluation of responses, likely prognosis and 
recurrence risks. The goal of the present work has been to report on the diagnostic 
criteria of patients with mild and moderate OI based on clinical and laboratory features, 
at the Skeletal Dysplasias Clinic at the Hospital for Special Surgery. We further used this 
information to catalogue genotype-phenotype correlations in our patient population 
and compare our findings to the published literature.  
 
MATERIALS & METHODS 
We obtained approval for this research from the Institutional Review Board of the 
Hospital for Special Surgery and conducted a retrospective chart review of 84 patients 
who were diagnosed with mild and moderate forms of OI at the Kathryn O. and Alan C. 
Greenberg Center for Skeletal Dysplasias at Hospital for Special Surgery. the Skeletal 
Dysplasias Clinic. We excluded patients diagnosed with more severe forms of OI (types 
II and III) or other metabolic bone or connective tissue disorders where fractures are a 
main clinical finding.  
 
In addition to the demographics, we collected all pertinent clinical information and 
evaluations leading to the diagnosis of mild or moderate OI in an index case. We 
collected data on fracture history, items identified in the physical exam and medical 
history including evaluation of auditory, ophthalmologic, cardiopulmonary, and skeletal 
systems and any treatment regimens and surgical procedures. In addition we reviewed 
radiographic findings (including X-rays, DXA scans, CAT scans, MRI, and ultrasounds), 
family history, and laboratory studies (biochemical and genetic testing, and other 
serum and urinalysis).  We hypothesized that definitive determination of a diagnosis of 
mild or moderate OI is by direct genomic sequencing.  
 
We de-identified our cohort for the analytic portion of this work and examined what 
correlation, if any, existed between clinical findings, laboratory test results, family 
history, and imaging results for individuals diagnosed with mild and moderate OI. In 
this work, we report on our findings on the nine most commonly expressed features of 
OI: fracture frequency, presence of blue/grey sclera, dentinogeneis imperfecta, hearing 
loss, short stature, scoliosis, bone density loss, bone deformity and ligament laxity. Our 
84 patients were grouped as (likely) having type I, type IV, or some other non-classic 
Sillence type OI. For each of the nine features, the proportions of patients in each group 
who exhibited the feature were calculated. To shed light on what role genotyping 
played in the clinical diagnosis, we subdivided each group into those with genotype 
information and those without. We then compared the percentage of genotyped 
patients versus un-genotyped patients, exhibiting each of the nine cardinal features.  
 
33 of the 84 patients had genotype information available and we used 30 of these 
individuals who had a mutation in either Col1α1 or Col1α2 to further examine their 
genotype-phenotype correlations. We catalogued the mutations of these patients, using 
the OI Variant Database when possible and mapped the mutations on the 




Figure 1A illustrates the number of patients in each category. Generally, there were 
more type I patients than type IV patients and within each group, most patients had not 
been genotyped. Figure 2 shows the fracture frequencies observed in each group and 
Figure 1B summarizes the proportion of patients in each group exhibiting the other 













Figure 3 – Genes implicated in genotyped patients.  
Type I – Patients in this group had a wide range in the number of fractures they had 
experienced from none (due to young age) to over 100 (due to multiple traumatic 
incidents such as motor vehicle accidents), however the majority had had 20 fractures 
or fewer. The presence of blue/grey sclera was the most prominent feature in this 
group, particularly if the patient was genotyped. 84% of the genotyped patients had 
blue/gray sclera while only 63% of the non-genotyped patients had blue/gray sclera, a 
difference of 21%. However the difference was not statistically significant (Chi-Square 
(1) = 1.76, p = 0.18). More than half of type I patients also had some degree of bone 
density loss (osteoporosis or osteopenia) and ligament laxity. Roughly a quarter of this 
group had DI, hearing loss and short stature. Bone deformity and scoliosis were only 
present in a small percentage of this group. While there were only six out of 51 patients 
with bone deformity, four or 21% of patients who were genotyped had bone deformity, 
while only two patients or 6% of those from the non-genotyped group had bone 
deformity. However, given the small sample of those with bone deformity, the 
difference was not statistically significant (Fisher’s Exact test = 0.18). Scoliosis was 
present in only six cases, but represented 16% of those in the non-genotyped group and 
only 5% of those in the genotyped group.  The difference was not statistically 
significant, given the small sample of those with scoliosis (Fisher’s Exact probability = 
0.39).  
 
Type IV – The sample size in this group was 25 patients. he fracture frequency in this 
group was quite variable from a few to over 100 with no major pattern of distribution. 
The other phenotypic features observed in most patients were short stature and 
ligament laxity. Roughly half of the patients had blue/grey sclera, DI, and bone density 
loss. Hearing loss, scoliosis and bone deformity were seen in roughly a third of the 
patients in this group. Besides hearing loss which was observed at the same 
approximate frequency in the genotyped, and not genotyped groups, features other 
than fractures were observed less frequently in the genotyped group. In the Type IV 
group 63% (15) had blue/gray sclera.  This was 71% of those in the non-genotyped 
group and only 45% of those in the genotyped group. The difference was not 
statistically significant (Fisher’s Exact probability = 0.24). Likewise, 52% (13) had 
dentinogenesis imperfecta.  This represented 64% of those in the non-genotyped group 
and only 36% of those in the genotyped group, a descriptive difference that was not 
statistically significant (Fisher’s Exact probability = 0.24).  In the Type IV group, 36% 
(9) had bone deformity.  43% of those in the non-genotyped group and only 27% of 
those in the genotyped group, a difference that was not statistically significant (Fisher’s 
Exact probability = .68). In the type IV group, 68% (17) had ligament laxity. This was 
79% of the non-genotyped group and only 55% of those in the genotyped group, a 
difference that was not statistically significant (Fisher’s Exact probability = 0.39) 
 
Genotype-Phenotype Relationship – Figure 3 illustrates the number and distribution 
of patients who were genotyped. There were more individuals with type I than type IV 
who had been genotyped. The majority of patients with type I OI had a mutation in 
Col1α1 while the majority of type IV patients had a mutation in Col1α2. The three 
patients with mutations in other genes are not currently typed within the classical 
Sillence types. We constructed a genotype-phenotype map of the individuals who had a 
mutation in either collagen type I gene (Figure 4). The mutations in our study subjects 
were all private and only common amongst family members. As Figure 4 illustrates, we 
observed nonsense, missense, frameshift and splice site mutations of Col1α1 at roughly 
the same frequency. For Col1α2, missense mutations were predominant and there were 
also frameshift mutations and one whole exon deletion. There appeared to be no 




Diagnostic Odyssey – One of the aims of this retrospective study was to examine 
how genetic testing is utilized in the clinic to address the diagnostic dilemma of mild 
and moderate forms of OI. Overall, we did not identify a set criteria that would be 
clinically diagnostic of OI type I or IV. Fracture frequency, the hallmark feature of OI, 
was highly variable in both patient groups ranging from few to over a hundred. 
Additionally, individuals who were typed outside the classical Sillence types (based 
on genotyping or a known mutation in the family), overlapped in terms of fracture 
frequency with type I and IV groups. Secondary features associated with OI 
including scleral hue, DI and hearing loss were also observed at variable rates and 
did not contribute to a definitive diagnosis or typing. As expected the skeletal 
phenotype was more involved in individuals with type IV with short stature and 
ligament laxity being predominant. Our data supports the claim that diagnosing and 
typing of mild and moderate types of OI strictly based on clinical features can be 
subjective. We observed that genotyping appears to be utilized most often in the 
most ambiguous cases. For example, a larger proportion of type I patients had been 
genotyped had bone deformity (a feature usually absent in these mild cases), 
compared to those not genotyped. In other words patients who had few fractures 
and were therefore likely to be type I but had bone deformities atypical of type I, 
presented as ambiguous cases that were resolved by genotyping. Likewise, in the 
type IV population, individuals who had not been genotyped were more likely than 
the genotyped individuals to exhibit all features except hearing loss. These are likely 
to have appeared as ambiguous cases in that their fracture frequency implied type 
IV, however, they appeared mildly or not at all affected with other features 
commonly seen in type. The exception to this observation is that type I patients with 
scoliosis were not genotyped at a higher rate, even though scoliosis is generally not 
expected to be present in mild cases. This could indicate that presence or absence of 
scoliosis does not provide strong clinical evidence in the diagnosis of OI. Of note, 
while there were the mentioned descriptive differences between genotyped and 
non-genotyped groups in the features, the differences were not statistically 
significant due in part to the small sample size and the small number of patients 
with the particular feature. 
 
Genotype-Phenotype Correlations – Our analysis of the genotype-phenotype data 
revealed that mutations in either Col1α1 or Col1α2 can lead to both type I and type 
IV OI with no identifiable correlation with to  mutation type, identity or location 
along the genes. Still, the majority of type I cases were due to Col1α1 mutations and 
almost all type IV cases were a result of Col1α2 mutations. In other words, 
mutations in Col1α1 appear to result in milder phenotypes than Col1α2. This would 
not be expected from a strictly stoichiometric standpoint given that each collagen 
polymer is composed of two alpha 1 and one alpha 2 chains. The explanation for the 
increased severity of a Col1α2 mutations compared to Col1α1, could instead be in 
the functional consequences of the mutations. This is consistent with the idea that 
type I OI is a result of quantitative defects caused by mutations in Col1α1 that result 
in collagen haploinsufficiency and more severe OI types are a result of qualitative 
defects due to mutations in Col1α2 that cause structural defects of collagen. These 
hypotheses may be answered with further functional studies that examine the 
protein products of these genes.   
 
There were several findings that were not consistent with other studies of 
genotype-phenotype correlations in OI, though we must keep in mind that the other 
studies acknowledge possible exceptions to their generalizations. First, since 
peptide translation occurs in the direction of C to N-terminus, it was expected that 
the earlier the mutation occurred in the sequence, the more severe the outcome. We 
did not observe any distinct pattern supporting this. In fact a notable exception was 
a type IV patient who had experienced over 50 fractures who had a frameshift 
mutation in the last exon (52) of Col1α1 (Figure 4). We hypothesize that either the 
mutation causes a structural defect in the alpha 1 chain or the patient has modifier 
genes that in combination with this mutation result in a more severe phenotype. 
Second, we observed that individuals in the same family with the same genotype 
had different phenotypes. This again could be due to modifier gene effects and in 
turn makes predicting likely prognoses based on genotype less reliable. Third, 
contrary to a general consensus that glycine substitutions result in structural 
defects of either chain and therefore more severe phenotypes, we found that glycine 
substitutions in the alpha 1 chain usually led to type I OI. Further functional analysis 
is needed to elucidate the mechanisms underlying these observations.  
 
Utility of Genetic Testing – In this study we illustrated that within our patient 
cohort, it was not practical to identify a set of clinical criteria for the definitive 
diagnosis or accurate typing of mild and moderate forms of OI. Traditionally, 
biochemical analysis has served as the (confirmatory) diagnostic test for OI, 
identifying culprits in about 90% of individuals with a clinical diagnosis (Wenstrup 
et al., 1990). In contrast, genetic testing is both minimally invasive and can identify 
the causative variants in more than 95% of affected individuals (Sykes et al., 
1990; Körkkö et al., 1998). In addition, in the prenatal setting, biochemical testing is 
limited to chorionic villus samples and can only identify qualitative defects, with a 
delay of 2-4 weeks for diagnosis in a time-sensitive context (Engel and Prockop, 
1991).  
 
When the primary purpose of investigation is to distinguish cases of child abuse and 
OI (though they are not mutually exclusive), genetic testing is extremely valuable. It 
is estimated that about 5% of suspected cases of child abuse are found to have OI 
(Marlowe et al., 2002). With the high detection rate of genomic, the residual risk 
that a child has OI after a negative genetic testing is less than 0.5%.  
 
Given these considerations, we conclude that genetic analysis should be used as a 
first tier testing modality in establishing and confirming a diagnosis of OI (in mild 
and moderate types). Biochemical testing still has value in follow-up studies that 
can shed light on to the pathogenicity of unclassified variants and functional 
analysis of splice-site mutations. Though in our study we could not establish any 
definitive genotype-phenotype correlations, as we collectively expand the variant 
database, we may start to see reoccurrences of previously assumed “private” 
mutations. In this way, having a genotype-phenotype map can help clinicians, 
patients and families gain insight into the likely course of the condition and 
therapeutic approaches.  
 
Genotype information is particularly helpful in appropriate selection of available 
therapies. Bisphosphonates and teriparatide are the two classes of medications 
currently prescribed in the treatment of OI. The mechanism of action of both drugs 
is to increase bone mass. Promoting an increase in bone mass is a wise approach in 
OI types that are due to a quantitative defect of collagen. However in patients whose 
gene alteration results in structurally defective collagen, promoting an increase in 
defective collagen synthesis is counter-productive. Furthermore, those with 
recessive types of OI that are phenotypically indistinguishable from classic types, 
would not respond in the same way to these treatments because the therapeutic 
target of these drugs do not align with the pathogenic pathways of recessive OI 
types. Additionally, bisphosphnates appear to be less effective in adults (Chevrel et 
al., 2006). Thus establishing an early and accurate diagnosis of OI plays an 
important role in optimizing the clinical management of OI patients.  
 
From a genetic counseling perspective, genotype information provides the most 
accurate assessment of recurrence risks and is perhaps most useful in the setting of 
prenatal and pre-implantation genetic diagnosis. This retrospective study reported 
on the diagnostic experience of patients with mild and moderate forms of OI at the 
Skeletal Dysplasias Clinic at the Hospital for Special Surgery and will serve as an 
expandable tool to inform both clinicians and patient families about the practical 
intricacies of the diagnosis and care of these patients.  
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